RYTM — Rhythm Pharmaceuticals, Inc.
RYTM dilution and offerings
- Dilution risk: Low
- Active shelf: S-3ASR (Feb 2026)
- Float: 62.3M shares
$93.44+0.94%
Last close: · regular session
Last 60 sessions
Dilution risk: low; active automatic shelf (S-3ASR, Feb 2026). Float: 62.3M shares. Latest SEC filing: SCHEDULE 13G on Oct 13, 2026. RYTM closed at $93.44 (+0.94%) on Nov 2, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for RYTM in the TickerWise workspace.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 283
- Website: https://www.rhythmtx.com
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Latest SEC filings for RYTM
Latest RYTM news
- Rhythm Pharmaceuticals Q3 2026 Earnings Preview Read article
- Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Read article
- Rhythm Pharmaceuticals (RYTM) Upgraded to Buy: Here's What You Should Know Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.